Geneva, Switzerland – June 13, 2026 – AvenCell Therapeutics has presented updated clinical results for its investigational CAR-T cell therapy, AVC-201-01, at the prestigious European Hematology Association (EHA) 2026 Congress. The findings from the Phase Ia RevSTAR-123 trial offer a compelling early glimpse into the potential of this first-in-class, switchable allogeneic CAR-T cell therapy for patients battling relapsed/refractory (R/R) acute myeloid leukemia (AML) and those with minimal residual disease (MRD)-positive disease, specifically targeting the interleukin-3 receptor alpha chain (CD123).
The presentation, delivered on June 13, 2026, highlighted encouraging preliminary efficacy and a manageable safety profile, bolstering the initial validation of AvenCell’s innovative RevCAR platform. This platform distinguishes itself through a dual approach: an allogeneic manufacturing process utilizing healthy donor T cells and a unique pharmacological "on-and-off" switch mechanism that allows for modulated CAR-T activation. These features are particularly significant in the context of R/R AML, a notoriously challenging disease where patient timelines are often critical and T cell quality can be compromised by prior intensive therapies.
The Innovation Behind AVC-201-01: A Switchable Allogeneic Approach
AVC-201-01 is engineered with two pivotal design elements aimed at overcoming the limitations of existing CAR-T therapies and addressing unmet needs in R/R AML.
Firstly, its allogeneic nature is a critical differentiator. Unlike autologous CAR-T therapies that require patient-specific T cell collection, genetic modification, and expansion – a process that can be lengthy and may not be feasible for heavily pre-treated patients with compromised T cell counts – AVC-201-01 is manufactured from a readily available pool of healthy donor T cells. This "off-the-shelf" capability is designed to significantly reduce manufacturing timelines, offering a crucial advantage for R/R AML patients who often face rapid disease progression and cannot afford delays. Furthermore, it circumvents the potential issue of poor T cell quality in patients who have undergone multiple lines of therapy.
Secondly, AVC-201-01 employs AvenCell’s proprietary RevCAR (Reversible Chimeric Antigen Receptor) platform. This innovative system hinges on a sophisticated modular design. The CAR-T cells themselves are engineered to be "dormant" until activated by a separately infused CD123-targeting module. This creates a precisely controllable pharmacological switch. Instead of relying on an irreversibly expressed CAR, clinicians can modulate the therapeutic activity of the CAR-T cells by adjusting the dose or infusion schedule of the targeting module. This "on-and-off" capability is of paramount clinical importance. While CD123 is a highly attractive target in AML due to its expression on leukemic blasts and stem cells, it is also present on normal hematopoietic progenitor cells and endothelial cells, posing a significant challenge for developing therapies with a favorable safety profile. The switchable nature of AVC-201-01 offers the potential to mitigate on-target, off-tumor toxicities by allowing for rapid cessation or reduction of CAR-T activity if adverse events arise.
RevSTAR-123 Trial: Early Efficacy and Safety Signals Emerge
The updated results presented from the Phase Ia RevSTAR-123 study provided the first clinical validation of AvenCell’s novel switchable allogeneic CD123 CAR-T platform in a high-risk AML patient population. The study enrolled 17 patients with R/R AML or MRD-positive AML, all of whom had CD123 expression.
Patient Population Characteristics:
The cohort represented a heavily pre-treated and high-risk group, underscoring the challenging nature of the disease setting. Patients had received a median of four prior lines of therapy. Notably, 10 of these patients had previously undergone allogeneic hematopoietic stem cell transplant (allo-HSCT), a significant indicator of disease aggressiveness and limited treatment options. Furthermore, nine patients were classified as having European LeukemiaNet (ELN) adverse risk disease, a prognostic classification associated with a poorer outcome.
Safety Profile:
The safety assessment of AVC-201-01 demonstrated a manageable profile, a critical consideration for any novel CAR-T therapy. Cytokine Release Syndrome (CRS), a common adverse event associated with CAR-T therapies, occurred in 13 out of the 17 treated patients. Encouragingly, only one of these cases was classified as Grade 3 CRS, with the majority being lower grade and presumed to be manageable. Importantly, the study reported no instances of immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GvHD), two potentially severe complications associated with CAR-T therapies, particularly allogeneic ones. There was also no treatment-related mortality observed within the study. A single dose-limiting toxicity (DLT) was identified at the highest dose level, providing valuable information for dose escalation.
Efficacy Observations:
The efficacy data, though preliminary, showed a promising trend, particularly at higher dose levels. Among the 8 evaluable patients at dose level (DL) 12 and DL 15, a meaningful clinical response was observed. Specifically, three patients achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh). Of these three responders, two achieved complete remissions that were also MRD-negative, indicating a deep and potentially durable response at the molecular level. This concentration of efficacy at higher doses suggests a dose-response relationship and provides a clear path for further dose optimization in subsequent trials. The early but meaningful signal in this challenging patient population supports the initial validation of AvenCell’s switchable allogeneic CD123 CAR-T platform.
Navigating the Competitive R/R AML Landscape
Should AVC-201-01 successfully navigate the development and regulatory pathways, it would enter a dynamic and evolving R/R AML market. This market is increasingly shaped by the confluence of biomarker-selected targeted therapies and the emergence of innovative cellular approaches.
Existing and Emerging Therapies:
A key commercial benchmark in this space is Astellas’ Xospata (gilteritinib), an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor. Xospata has gained approval for R/R AML patients with FLT3 mutations, benefiting from its outpatient administration and robust Phase III survival data. However, its application is limited to a specific, molecularly defined subgroup of patients.
In contrast, AVC-201-01 aims for broader applicability by targeting CD123, a marker expressed on a wider patient population, including those without actionable mutations. The success of AVC-201-01 will hinge on its ability to demonstrate durable MRD conversion, a manageable toxicity profile, and its effectiveness as a bridge to potentially curative allogeneic stem cell transplantation. These factors will be crucial in justifying the complexity and resource intensity associated with a cellular therapy.
The clinical relevance of CD123 as a myeloid target is further reinforced by AbbVie’s Decnupaz (pivekimab sunirine), a CD123-directed antibody-drug conjugate (ADC). While approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN), Decnupaz is also under evaluation in AML through the pivotal Phase III REVIVAL study. The success of CD123-targeting strategies in the clinic validates the therapeutic potential of this antigen. AvenCell’s AVC-201-01 differentiates itself through its unique switchable allogeneic CAR-T design. Its ultimate value proposition will depend on its capacity to deliver deeper and more sustained remissions compared to other CD123-directed therapies, particularly non-cellular approaches.
Commercial Outlook and Future Directions
From a commercial perspective, AVC-201-01 presents an attractive proposition with inherent high-risk factors, as is typical for early-stage drug development.
Commercial Advantages:
The allogeneic format holds significant promise for streamlining manufacturing, potentially reducing lead times and enhancing scalability. This is a critical consideration for the rapidly evolving R/R AML market where swift intervention is often necessary. Furthermore, the switchable CD123 targeting module offers a potential advantage in terms of safety and dose control, providing a crucial mechanism to navigate the narrow therapeutic window associated with targeting CD123.
Key Determinants for Adoption:
However, the successful adoption of AVC-201-01 will be contingent on robust clinical evidence demonstrating:
- Deeper Responses: Achieving complete remissions with significant tumor burden reduction.
- MRD Negativity: Eradicating disease at the molecular level, a strong predictor of long-term outcomes.
- Durable Remissions: Sustained disease control over extended periods.
- Manageable Toxicity: A favorable safety profile, particularly concerning CRS and cytopenias, that allows for patient tolerance and continuation of therapy.
- Effective Bridging to Transplant: Demonstrating its utility in preparing patients for and facilitating successful allogeneic stem cell transplantation, the current standard of care for many R/R AML patients.
Conclusion:
In conclusion, AvenCell Therapeutics’ AVC-201-01 represents an early but significant validation of a next-generation CAR-T cell therapy concept for AML. While the updated results from the RevSTAR-123 trial are encouraging, AVC-201-01 is not yet a practice-changing therapy. Its future success will depend on continued clinical development, demonstrating clear and sustained benefits in larger patient populations, and navigating the complexities of regulatory approval and market access. The innovative switchable allogeneic design, however, positions it as a compelling candidate to address critical unmet needs in the challenging landscape of relapsed and refractory AML.
About the Author
